Abstract
One of the most serious complications of assisted reproduction techniques is ovarian hyperstimulation syndrome (OHSS). OHSS not only increases morbidity and mortality in IFV cycles, but also causes significant other problems, as cancelled in vitro fertilization (IVF) cycles, prolonged hospitalization, causing emotional and sociofinancial consequences. Several treatments for OHSS have been proposed and among these Cabergoline (Cb2). Despite the above-mentioned beneficial effect, Cb2 has not been widely used in everyday's clinical practice. With our study, we try to review all studies with strong evidence examining Cb2 use for OHSS prevention.
MeSH terms
-
Cabergoline
-
Chorionic Gonadotropin / adverse effects
-
Chorionic Gonadotropin / pharmacology
-
Dopamine Agonists / adverse effects
-
Dopamine Agonists / therapeutic use*
-
Ergolines / adverse effects
-
Ergolines / therapeutic use*
-
Evidence-Based Medicine
-
Female
-
Fertility Agents, Female / adverse effects
-
Fertility Agents, Female / pharmacology
-
Gene Expression Regulation / drug effects
-
Humans
-
Ovarian Hyperstimulation Syndrome / drug therapy*
-
Ovarian Hyperstimulation Syndrome / metabolism
-
Ovarian Hyperstimulation Syndrome / prevention & control
-
Ovary / drug effects*
-
Ovary / metabolism
-
Phosphorylation / drug effects
-
Protein Processing, Post-Translational / drug effects
-
Signal Transduction / drug effects
-
Vascular Endothelial Growth Factor A / biosynthesis
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism
-
Vascular Endothelial Growth Factor Receptor-2 / biosynthesis
-
Vascular Endothelial Growth Factor Receptor-2 / genetics
-
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Substances
-
Chorionic Gonadotropin
-
Dopamine Agonists
-
Ergolines
-
Fertility Agents, Female
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factor Receptor-2
-
Cabergoline